Excellent - I now have comprehensive textbook content, diagrams, and the latest EULAR 2023 guideline. Here is a complete, structured account of osteoarthritis:
Osteoarthritis - Complete Overview
Definition
Osteoarthritis (OA), also called degenerative joint disease, is characterized by failed repair of synovial joint tissues after intra-articular stress. The resulting breakdown of cartilage and bone leads to pain, stiffness, and functional disability. It is the most common musculoskeletal disorder worldwide.
"Although the term osteoarthritis implies an inflammatory disease, it is primarily a degenerative disorder of articular cartilage, with inflammation acting as a secondary contributor."
- Robbins & Kumar Basic Pathology
Pathogenesis
The pathogenesis progresses in three stages:
Stage 1 - Chondrocyte Injury:
Biomechanical stress (genetic or mechanical) injures chondrocytes. Type II collagen and proteoglycan synthesis is disrupted.
Stage 2 - Early OA:
Injured chondrocytes proliferate and release inflammatory mediators - PGE2, NO, TNF-alpha. Matrix metalloproteinases (MMPs) degrade collagen and proteoglycans. TGF-beta and BMP attempt repair but degradation exceeds it.
Stage 3 - Late OA:
- Chondrocyte apoptosis and dropout
- Full-thickness cartilage loss
- Loose bodies (joint mice) from dislodged cartilage/bone fragments
- Subchondral bone changes (sclerosis, cysts)
- Osteophyte formation at joint margins
- Bone eburnation - exposed subchondral bone becomes polished like ivory
Types
| Type | Description |
|---|
| Primary (Idiopathic) OA | No identifiable cause; associated with aging, genetics, female sex, obesity |
| Secondary OA | Due to an identifiable underlying cause (see below) |
Secondary causes (Grainger & Allison's Diagnostic Radiology):
- Trauma (acute or chronic repetitive)
- Metabolic: Hemochromatosis, Wilson disease, Ochronosis
- Endocrine: Acromegaly, Hypothyroidism, Hyperparathyroidism, Diabetes
- Crystal deposition: Gout, CPPD (pseudogout)
- Inflammatory arthritis (burnt-out RA)
- Avascular necrosis
- Congenital joint deformity (e.g., DDH, slipped upper femoral epiphysis)
- Ligamentous laxity (Ehlers-Danlos syndrome)
Epidemiology & Risk Factors
- Affects >50 million people worldwide; women disproportionately affected
- Prevalence increases exponentially after age 50; ~40% of people over 70 are affected
- Knee OA is the most common form in clinical practice
Non-modifiable risk factors:
- Older age
- Female sex (especially post-menopausal)
- Family history / genetic predisposition (GDF5, RUNX2, SMAD3 loci)
- Black race, lower socioeconomic status
Modifiable risk factors:
- Obesity - strongest modifiable risk factor for knee OA (causative via BMI shown in Mendelian randomization)
- Joint injury (previous fracture, meniscal tear, ligament injury)
- Repetitive occupational loading
- Metabolic syndrome, higher leptin levels
Joints Commonly Involved
Knees (most common weight-bearing joint affected)
Hips
Lower lumbar and cervical vertebrae
Proximal interphalangeal joints (PIP) and
Distal interphalangeal joints (DIP) of fingers
First carpometacarpal (CMC) joint of thumb
First metatarsophalangeal joint (big toe - hallux rigidus)
Note: Wrists, ankles, and shoulders are spared in primary OA (involvement suggests secondary OA).
Clinical Features
Symptoms
| Symptom | Details |
|---|
| Joint pain | Worse with use/activity (mechanical), relieved by rest - cardinal feature |
| Morning stiffness | Present but brief (<30 minutes) - key differentiator from RA (>1 hour) |
| Start-up pain / gelling | Pain/stiffness after sitting still, eases after a few steps |
| Crepitus | Grating/grinding sensation on joint movement |
| Joint swelling | Cool, non-inflammatory effusion (bony swelling from osteophytes) |
| Restricted range of movement | Progressive limitation of joint motion |
| Instability/giving way | In knee OA due to muscle weakness or ligament laxity |
| Night pain | Occurs in advanced disease only |
Signs
- Bony enlargement of joint margins (osteophytes palpable)
- Heberden nodes - osteophytes at DIP joints of fingers (more common in women)
- Bouchard nodes - osteophytes at PIP joints of fingers
- Varus deformity (bow legs) - medial compartment knee OA (commonest)
- Valgus deformity (knock knees) - lateral compartment knee OA
- Crepitus on passive joint movement
- Tenderness along joint line
- Antalgic gait in hip or knee OA
- No significant warmth or systemic features (unlike RA)
- No joint fusion (ankylosis) - unlike RA
OA vs RA - Comparison
| Feature | Osteoarthritis | Rheumatoid Arthritis |
|---|
| Mechanism | Mechanical cartilage degeneration | Autoimmune (T cells, ACPA, RF) |
| Joints involved | Weight-bearing (knee, hip), DIP | Small joints of hands first; symmetric; PIP, MCP |
| Morning stiffness | <30 minutes | >1 hour |
| Swelling | Hard (bony osteophytes) | Soft (synovial proliferation) |
| Systemic features | None | Yes (fatigue, fever, extra-articular) |
| Serum antibodies | None | RF, anti-CCP (ACPA) |
| Inflammation | Secondary, mild | Primary, severe |
| Ankylosis | Does NOT occur | Yes (fibrous then bony) |
| Pannus | No | Yes |
Histopathology / Morphology
From Robbins & Kumar Basic Pathology:
- Early: Cartilage fibrillation (vertical clefts), chondrocyte proliferation into clusters
- Advanced: Full-thickness cartilage loss, chondrocyte dropout
- Bone eburnation: Exposed subchondral bone polished like ivory by opposing surface
- Subchondral cysts: Synovial fluid forced into bone via micro-fractures (ball-valve mechanism)
- Osteophytes: Fibrocartilage-capped bone outgrowths at joint margins; gradually ossify
- Loose bodies (joint mice): Dislodged fragments of cartilage/bone floating in joint
- Synovium: Only mildly congested/fibrotic with scattered chronic inflammatory cells - contrast with RA's dense synovitis
Investigations
Bloods (Usually Normal in OA)
| Test | Result in OA | Purpose |
|---|
| ESR / CRP | Normal | To exclude inflammatory arthritis |
| Rheumatoid factor | Negative | Exclude RA |
| Anti-CCP | Negative | Exclude RA |
| Serum uric acid | Normal | Exclude gout |
| FBC | Normal | Baseline; rule out anaemia of chronic disease |
| ALP | Normal (elevated in Paget's) | |
| Blood glucose | Screen for metabolic association | |
Imaging
X-ray (Weight-Bearing Standing Views) - GOLD STANDARD for diagnosis
The LOSS mnemonic:
- L - Loss of joint space (narrowing, typically medial compartment in knee)
- O - Osteophytes (bony spurs at joint margins)
- S - Subchondral sclerosis (increased bone density beneath cartilage)
- S - Subchondral cysts (geodes - round radiolucent areas)
Additional X-ray features:
- Varus/valgus malalignment
- Loose bodies
- Note: Radiographic severity correlates poorly with pain and disability
MRI Knee
- Not routine; used if meniscal tear, ligament injury, or AVN suspected
- Shows bone marrow lesions (BMLs) - correlate with pain
- Reveals synovitis, cartilage integrity, and soft tissue abnormalities
Ultrasound
- Detects effusion, synovitis, Baker's cyst
- Guides intra-articular injections
Synovial Fluid Analysis (if effusion present)
| Feature | OA | Inflammatory/Septic |
|---|
| Appearance | Clear/yellow (non-inflammatory) | Turbid/opaque |
| WBC | <2000/mm³ | >2000 (inflammatory), >50,000 (septic) |
| Crystals | None (unless coexistent CPPD) | Urate (gout), CPP (pseudogout) |
Management
Step 1 - Non-Pharmacological (First-Line, Always)
EULAR 2023 Recommendations for Hip & Knee OA (PMID: 38212040):
- Individualised multicomponent management plan - tailored to patient's needs, comorbidities, preferences
- Education and self-management - patient empowerment about disease, activity, weight
- Exercise therapy (STRONGEST recommendation)
- Land-based exercise (strengthening + aerobic) - strong evidence
- Low-impact aerobics: swimming, cycling, walking
- Quadriceps strengthening especially important in knee OA
- Aquatic/hydrotherapy for those unable to tolerate land-based exercise
- Tailored dosage and progressive intensity
- Weight loss - if BMI >25; moderate-strong evidence (reduces load on joint ~4x body weight at knee)
- Walking aids - cane (in contralateral hand), walking frame
- Footwear and insoles - appropriate footwear; lateral wedge insoles for medial compartment OA
- Work advice - activity modification, pacing
- Behaviour change techniques - improve adherence to lifestyle interventions
Campbell's Operative Orthopaedics (AAOS-based evidence):
| Evidence Level | Intervention |
|---|
| Strong | Physical activity, low-impact aerobic strengthening exercise, NSAIDs |
| Moderate | Weight loss (BMI >25) |
| Inconclusive | Electrotherapy, manual therapy, bracing, intra-articular corticosteroids, PRP, acetaminophen, opioids |
| Moderate-Strong Against | Acupuncture, insoles, glucosamine/chondroitin, hyaluronic acid, needle lavage |
Step 2 - Pharmacological
Analgesia (step-up approach):
| Drug | Use | Notes |
|---|
| Paracetamol (Acetaminophen) | Mild pain, step 1 | Ceiling dose 4g/day; less effective than previously thought for OA |
| Topical NSAIDs (diclofenac gel, ibuprofen gel) | Knee/hand OA | First-line for peripheral joints; fewer GI side effects |
| Oral NSAIDs (ibuprofen, naproxen, celecoxib) | Moderate-severe pain | Most effective analgesic; use with PPI; caution in elderly (renal, GI, CV risk) |
| Topical capsaicin | Adjunct in knee OA | Depletes substance P |
| Duloxetine (SNRI) | Central sensitization, chronic pain | OARSI/ACR recommend for OA with central pain features |
| Tramadol | Short-term; moderate-severe pain | Avoid long-term; addiction risk |
| Strong opioids | Last resort before surgery | Short-term only; significant risk in elderly |
Intra-articular Injections:
| Injection | Evidence | Duration |
|---|
| Corticosteroid (triamcinolone, methylprednisolone) | Moderate; good for acute flares with effusion | 4-12 weeks; max 3-4/year (cartilage damage risk) |
| Hyaluronic acid (viscosupplementation) | Moderate-against; AAOS recommends against | Variable; 6-12 months claimed |
| PRP (Platelet-rich plasma) | Inconclusive | Experimental; not standard of care |
Step 3 - Surgical
Indications: Failed conservative therapy + significant pain + functional disability + radiological correlation.
| Procedure | When Used | Notes |
|---|
| Arthroscopic lavage/debridement | Limited role; may help mechanical symptoms (locking) | Not effective for pure OA; no better than placebo in trials |
| Osteotomy (tibial or femoral) | Younger patients (<55-60), unicompartmental OA with malalignment | Realigns weight-bearing axis to offload diseased compartment |
| Unicompartmental knee arthroplasty (UKA) | Single compartment disease; well-preserved ROM | Less invasive; faster recovery; can convert to TKR later |
| Total Knee Replacement (TKR) | Severe tricompartmental OA | Most common elective orthopaedic procedure; 90-95% 10-year survival |
| Total Hip Replacement (THR) | Severe hip OA | Excellent outcomes; >95% 10-year survival |
Total Knee Replacement is indicated when:
- Severe pain at rest and night pain
- Significant functional limitation (unable to walk >100m)
- Radiological grade III-IV OA (Kellgren-Lawrence)
- Failed 6-12 months of conservative treatment
Kellgren-Lawrence Grading (X-ray Classification)
| Grade | Features |
|---|
| 0 | Normal |
| I | Doubtful narrowing; possible osteophytes |
| II | Definite osteophytes; possible narrowing |
| III | Moderate narrowing; multiple osteophytes; some sclerosis |
| IV | Severe narrowing; large osteophytes; marked sclerosis; possible deformity |
Prognosis
- OA is a progressive, irreversible condition - no disease-modifying treatments exist yet
- Rate of progression is variable and unpredictable
- Radiographic severity correlates poorly with symptoms
- Up to 20% of patients continue to have significant pain after total knee replacement
- Weight loss and exercise can slow progression and significantly improve quality of life
Sources:
- Robbins & Kumar Basic Pathology - Pathogenesis and Morphology
- Firestein & Kelley's Textbook of Rheumatology - Pain mechanisms and risk factors
- Grainger & Allison's Diagnostic Radiology - Classification and imaging
- Campbell's Operative Orthopaedics, 15th Ed 2026 - Surgical management and AAOS evidence
- EULAR 2023 Non-pharmacological recommendations for hip/knee OA (PMID: 38212040)